Symbols / CCCC Stock $2.88 -3.03% C4 Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
CCCC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Andrew J. Hirsch M.B.A.
Exch · Country NMS · United States
Market Cap 281.03M
Enterprise Value 92.47M
Income -104.99M
Sales 35.95M
FCF (ttm) -54.30M
Book/sh 2.65
Cash/sh 2.55
Employees 104
Insider 10d —
IPO Oct 02, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.29
PEG —
P/S 7.82
P/B 1.09
P/C —
EV/EBITDA -0.90
EV/Sales 2.57
Quick Ratio 7.60
Current Ratio 7.81
Debt/Eq 23.38
LT Debt/Eq —
EPS (ttm) -1.27
EPS next Y -1.26
EPS Growth —
Revenue Growth 112.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-26
ROA -18.43%
ROE -44.44%
ROIC —
Gross Margin 75.03%
Oper. Margin -210.10%
Profit Margin -292.08%
Shs Outstand 97.58M
Shs Float 66.76M
Insider Own 8.65%
Instit Own 77.65%
Short Float 22.79%
Short Ratio 6.94
Short Interest 21.04M
52W High 3.82
vs 52W High -24.61%
52W Low 1.21
vs 52W Low 138.02%
Beta 2.86
Impl. Vol. 42.32%
Rel Volume 0.84
Avg Volume 2.54M
Volume 2.14M
Target (mean) $11.57
Tgt Median $7.00
Tgt Low $6.00
Tgt High $30.00
# Analysts 7
Recom Strong_buy
Prev Close $2.97
Price $2.88
Change -3.03%
About

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.57
Mean price target
2. Current target
$2.88
Latest analyst target
3. DCF / Fair value
$-10.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.88
Low
$6.00
High
$30.00
Mean
$11.57

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-27 main Barclays Overweight → Overweight $7
2026-02-23 main Brookline Capital Buy → Buy $30
2025-12-17 main Barclays Overweight → Overweight $5
2025-12-02 init TD Cowen — → Buy —
2025-09-23 main Wells Fargo Overweight → Overweight $10
2025-09-23 main Barclays Overweight → Overweight $10
2025-09-22 reit Stephens & Co. Overweight → Overweight $6
2025-09-17 init Barclays — → Overweight $8
2025-09-15 up Stephens & Co. Equal-Weight → Overweight $6
2025-09-04 init Guggenheim — → Buy $8
2024-12-19 up Wells Fargo Equal-Weight → Overweight $12
2024-11-18 init Stephens & Co. — → Equal-Weight $4
2024-08-06 reit BMO Capital Outperform → Outperform $20
2024-05-09 main Wells Fargo Equal-Weight → Equal-Weight $8
2024-05-09 main Stifel Buy → Buy $14
2024-02-26 main Morgan Stanley Equal-Weight → Equal-Weight $8
2024-02-23 reit Stifel Buy → Buy $13
2024-01-29 up JP Morgan Underweight → Neutral $6
2023-12-13 up Stifel Hold → Buy $12
2023-11-06 up Morgan Stanley Underweight → Equal-Weight $1
News
RSS: Latest CCCC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 GROGAN DONNA ROY M.D. Director — 5,370 $2.70 $14,499
2026-04-01 ANDERSON KENNETH CARL Director — 4,259 $2.70 $11,499
2026-02-13 BOYLE SCOTT N Officer — 200,000 $0.00 $0
2026-02-13 BOYLE SCOTT N Officer — 25,950 — —
2026-02-13 ADAMS KENDRA Chief Financial Officer — 240,000 $0.00 $0
2026-02-13 ADAMS KENDRA Chief Financial Officer — 34,700 — —
2026-02-13 MOSSLER MARK Officer — 56,980 $0.00 $0
2026-02-13 MOSSLER MARK Officer — 9,420 — —
2026-02-13 MAHANEY PAIGE Officer — 240,000 $0.00 $0
2026-02-13 MAHANEY PAIGE Officer — 7,050 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
35.95
+1.02%
35.58
+71.44%
20.76
-33.25%
31.10
Operating Revenue
35.95
+1.02%
35.58
+71.44%
20.76
-33.25%
31.10
Operating Expense
140.44
-8.07%
152.76
-4.40%
159.79
-0.52%
160.63
Research And Development
104.24
-5.78%
110.64
-6.01%
117.71
-0.11%
117.84
Selling General And Administration
36.20
-14.07%
42.12
+0.10%
42.08
-1.65%
42.79
General And Administrative Expense
36.20
-14.07%
42.12
+0.10%
42.08
-1.65%
42.79
Salaries And Wages
25.34
-18.99%
31.28
+3.42%
30.24
-0.99%
30.55
Other Gand A
10.86
+0.12%
10.85
-8.37%
11.84
-3.32%
12.24
Total Expenses
140.44
-8.07%
152.76
-4.40%
159.79
-0.52%
160.63
Operating Income
-104.49
+10.83%
-117.18
+15.72%
-139.03
-7.33%
-129.53
Total Operating Income As Reported
-115.22
+3.67%
-119.61
+13.97%
-139.03
-7.33%
-129.53
EBITDA
-102.53
+11.12%
-115.36
+9.85%
-127.96
-2.96%
-124.28
Normalized EBITDA
-91.80
+18.71%
-112.92
+11.32%
-127.34
-2.46%
-124.28
Reconciled Depreciation
1.96
+7.76%
1.82
-3.30%
1.88
+12.17%
1.68
EBIT
-104.49
+10.83%
-117.18
+9.75%
-129.84
-3.08%
-125.96
Total Unusual Items
-10.73
-340.42%
-2.44
-292.43%
-0.62
0.00
Total Unusual Items Excluding Goodwill
-10.73
-340.42%
-2.44
-292.43%
-0.62
0.00
Special Income Charges
-10.73
-340.42%
-2.44
-292.43%
-0.62
0.00
Other Special Charges
—
—
0.62
—
Impairment Of Capital Assets
10.73
—
—
—
Restructuring And Mergern Acquisition
0.00
-100.00%
2.44
0.00
—
Net Income
-104.99
+0.31%
-105.32
+20.51%
-132.49
-3.37%
-128.18
Pretax Income
-104.87
+0.30%
-105.19
+19.84%
-131.21
-2.37%
-128.18
Net Non Operating Interest Income Expense
10.35
-28.28%
14.43
+70.98%
8.44
+520.97%
1.36
Interest Expense Non Operating
—
0.00
-100.00%
1.37
-38.04%
2.22
Net Interest Income
10.35
-28.28%
14.43
+70.98%
8.44
+520.97%
1.36
Interest Expense
—
0.00
-100.00%
1.37
-38.04%
2.22
Interest Income Non Operating
10.35
-28.28%
14.43
+47.05%
9.81
+174.46%
3.58
Interest Income
10.35
-28.28%
14.43
+47.05%
9.81
+174.46%
3.58
Other Income Expense
-10.73
-340.42%
-2.44
-292.43%
-0.62
—
Tax Provision
0.12
-7.63%
0.13
-89.77%
1.28
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
-2.25
-340.42%
-0.51
-292.43%
-0.13
0.00
Net Income Including Noncontrolling Interests
-104.99
+0.31%
-105.32
+20.51%
-132.49
-3.37%
-128.18
Net Income From Continuing Operation Net Minority Interest
-104.99
+0.31%
-105.32
+20.51%
-132.49
-3.37%
-128.18
Net Income From Continuing And Discontinued Operation
-104.99
+0.31%
-105.32
+20.51%
-132.49
-3.37%
-128.18
Net Income Continuous Operations
-104.99
+0.31%
-105.32
+20.51%
-132.49
-3.37%
-128.18
Normalized Income
-96.51
+6.65%
-103.39
+21.68%
-132.00
-2.99%
-128.18
Net Income Common Stockholders
-104.99
+0.31%
-105.32
+20.51%
-132.49
-3.37%
-128.18
Diluted EPS
—
-1.52
+43.07%
-2.67
-1.91%
-2.62
Basic EPS
—
-1.52
+43.07%
-2.67
-1.91%
-2.62
Basic Average Shares
—
69.37
+39.75%
49.64
+1.59%
48.86
Diluted Average Shares
—
69.37
+39.75%
49.64
+1.59%
48.86
Diluted NI Availto Com Stockholders
-104.99
+0.31%
-105.32
+20.51%
-132.49
-3.37%
-128.18
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
359.07
+2.71%
349.60
-7.13%
376.45
-12.62%
430.84
Current Assets
258.11
+0.13%
257.77
-4.95%
271.19
-5.69%
287.56
Cash Cash Equivalents And Short Term Investments
248.54
+1.48%
244.90
-3.46%
253.68
-8.14%
276.15
Cash And Cash Equivalents
74.60
+34.42%
55.50
-56.16%
126.59
+325.46%
29.75
Other Short Term Investments
173.93
-8.17%
189.41
+49.03%
127.09
-48.42%
246.40
Receivables
2.40
-22.60%
3.10
-73.71%
11.80
+701.02%
1.47
Accounts Receivable
2.40
-22.60%
3.10
-73.71%
11.80
+701.02%
1.47
Prepaid Assets
—
—
—
—
Other Current Assets
7.17
-26.52%
9.76
+70.98%
5.71
-42.51%
9.93
Total Non Current Assets
100.97
+9.94%
91.83
-12.76%
105.26
-26.54%
143.28
Net PPE
45.28
-28.56%
63.38
-10.85%
71.09
-8.29%
77.52
Gross PPE
56.05
-22.81%
72.61
-7.91%
78.85
-7.93%
85.64
Accumulated Depreciation
-10.78
-16.68%
-9.24
-18.97%
-7.76
+4.43%
-8.12
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
—
—
Machinery Furniture Equipment
2.15
+0.00%
2.15
+0.61%
2.14
+12.62%
1.90
Construction In Progress
—
—
0.00
-100.00%
0.18
Other Properties
49.35
-24.94%
65.75
-8.68%
72.00
-8.72%
78.87
Leases
4.55
-3.48%
4.71
+0.00%
4.71
+0.64%
4.68
Investments And Advances
48.56
+117.20%
22.36
-20.17%
28.01
-54.06%
60.96
Other Non Current Assets
7.13
+16.86%
6.10
-1.10%
6.17
+28.32%
4.80
Total Liabilities Net Minority Interest
102.49
-23.30%
133.62
+2.52%
130.34
-7.96%
141.61
Current Liabilities
33.03
-26.88%
45.18
+5.64%
42.77
-4.00%
44.55
Payables And Accrued Expenses
4.12
-63.86%
11.39
-10.22%
12.69
+15.40%
11.00
Payables
0.86
-35.39%
1.33
-8.16%
1.45
+23.38%
1.17
Accounts Payable
0.86
-35.39%
1.33
-8.16%
1.45
+23.38%
1.17
Current Accrued Expenses
3.26
-67.62%
10.06
-10.49%
11.24
+14.44%
9.82
Pensionand Other Post Retirement Benefit Plans Current
8.66
+16.53%
7.43
+1.14%
7.34
+7.51%
6.83
Current Debt And Capital Lease Obligation
6.37
+10.27%
5.77
+10.63%
5.22
-25.30%
6.99
Current Debt
—
—
—
2.29
Other Current Borrowings
—
—
—
2.29
Current Capital Lease Obligation
6.37
+10.27%
5.77
+10.63%
5.22
+11.04%
4.70
Current Deferred Liabilities
12.49
-33.24%
18.71
+20.95%
15.47
-6.90%
16.62
Current Deferred Revenue
12.49
-33.24%
18.71
+20.95%
15.47
-6.90%
16.62
Other Current Liabilities
1.40
-25.23%
1.87
-8.42%
2.04
-34.39%
3.11
Total Non Current Liabilities Net Minority Interest
69.46
-21.46%
88.44
+0.99%
87.57
-9.78%
97.06
Long Term Debt And Capital Lease Obligation
53.62
-10.61%
59.98
-8.78%
65.76
-17.97%
80.17
Long Term Debt
—
—
—
9.20
Long Term Capital Lease Obligation
53.62
-10.61%
59.98
-8.78%
65.76
-7.35%
70.97
Non Current Deferred Liabilities
15.84
-44.33%
28.46
+30.45%
21.81
+29.12%
16.89
Non Current Deferred Revenue
15.84
-44.33%
28.46
+30.45%
21.81
+29.12%
16.89
Stockholders Equity
256.59
+18.80%
215.99
-12.24%
246.11
-14.91%
289.23
Common Stock Equity
256.59
+18.80%
215.99
-12.24%
246.11
-14.91%
289.23
Capital Stock
0.01
+28.57%
0.01
+16.67%
0.01
+20.00%
0.01
Common Stock
0.01
+28.57%
0.01
+16.67%
0.01
+20.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
96.91
+37.22%
70.63
+16.80%
60.47
+23.49%
48.97
Ordinary Shares Number
96.91
+37.22%
70.63
+16.80%
60.47
+23.49%
48.97
Additional Paid In Capital
995.22
+17.14%
849.62
+9.68%
774.62
+12.38%
689.26
Retained Earnings
-738.69
-16.57%
-633.70
-19.93%
-528.38
-33.47%
-395.89
Gains Losses Not Affecting Retained Earnings
0.05
-5.66%
0.05
+141.73%
-0.13
+96.93%
-4.14
Other Equity Adjustments
0.05
-5.66%
0.05
+141.73%
-0.13
+96.93%
-4.14
Total Equity Gross Minority Interest
256.59
+18.80%
215.99
-12.24%
246.11
-14.91%
289.23
Total Capitalization
256.59
+18.80%
215.99
-12.24%
246.11
-17.53%
298.43
Working Capital
225.08
+5.87%
212.59
-6.93%
228.42
-6.00%
243.01
Invested Capital
256.59
+18.80%
215.99
-12.24%
246.11
-18.16%
300.72
Total Debt
59.98
-8.78%
65.76
-7.35%
70.98
-18.56%
87.15
Capital Lease Obligations
59.98
-8.78%
65.76
-7.35%
70.98
-6.20%
75.67
Net Tangible Assets
256.59
+18.80%
215.99
-12.24%
246.11
-14.91%
289.23
Tangible Book Value
256.59
+18.80%
215.99
-12.24%
246.11
-14.91%
289.23
Available For Sale Securities
48.56
+117.20%
22.36
-20.17%
28.01
-54.06%
60.96
Investmentin Financial Assets
48.56
+117.20%
22.36
-20.17%
28.01
-54.06%
60.96
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-98.69
-51.47%
-65.16
+39.01%
-106.84
-0.85%
-105.94
Cash Flow From Continuing Operating Activities
-98.69
-51.47%
-65.16
+39.01%
-106.84
-0.85%
-105.94
Net Income From Continuing Operations
-104.99
+0.31%
-105.32
+20.51%
-132.49
-3.37%
-128.18
Depreciation Amortization Depletion
1.96
+7.76%
1.82
-3.30%
1.88
+12.17%
1.68
Depreciation
—
—
—
1.68
Depreciation And Amortization
1.96
+7.76%
1.82
-3.30%
1.88
+12.17%
1.68
Other Non Cash Items
0.10
+1550.00%
0.01
-98.76%
0.48
-32.40%
0.71
Stock Based Compensation
19.10
-35.61%
29.66
+8.91%
27.23
-9.27%
30.02
Asset Impairment Charge
17.17
+167.36%
6.42
+4.25%
6.16
+4.46%
5.90
Operating Gains Losses
—
—
0.62
—
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-29.28
-482.87%
7.65
+210.23%
-6.94
+58.65%
-16.78
Change In Receivables
0.70
-91.94%
8.70
+184.22%
-10.33
-343.33%
4.24
Changes In Account Receivables
0.70
-91.94%
8.70
+184.22%
-10.33
-343.33%
4.24
Change In Prepaid Assets
1.14
+126.43%
-4.33
-258.94%
2.72
+601.80%
0.39
Change In Payables And Accrued Expense
-6.52
-370.20%
-1.39
-187.22%
1.59
-9.20%
1.75
Change In Accrued Expense
-6.05
-377.43%
-1.27
-196.28%
1.32
-74.11%
5.08
Change In Payable
-0.47
-293.28%
-0.12
-143.59%
0.27
+108.19%
-3.33
Change In Account Payable
-0.47
-293.28%
-0.12
-143.59%
0.27
+108.19%
-3.33
Change In Other Working Capital
-18.84
-290.57%
9.88
+162.04%
3.77
+116.65%
-22.65
Change In Other Current Liabilities
-5.77
-10.63%
-5.22
-11.16%
-4.70
-826.04%
-0.51
Investing Cash Flow
-8.60
+83.22%
-51.27
-132.38%
158.35
+171.04%
58.42
Cash Flow From Continuing Investing Activities
-8.60
+83.22%
-51.27
-132.38%
158.35
+171.04%
58.42
Net PPE Purchase And Sale
-0.61
-237.22%
-0.18
+89.46%
-1.71
+68.92%
-5.50
Purchase Of PPE
-0.61
-237.22%
-0.18
+89.46%
-1.71
+68.92%
-5.50
Sale Of PPE
—
—
—
—
Capital Expenditure
-0.61
-237.22%
-0.18
+89.46%
-1.71
+68.92%
-5.50
Net Investment Purchase And Sale
-7.99
+84.35%
-51.09
-131.92%
160.06
+150.41%
63.92
Purchase Of Investment
-227.07
+20.13%
-284.32
-118.88%
-129.90
+40.83%
-219.53
Sale Of Investment
219.08
-6.07%
233.23
-19.56%
289.95
+2.30%
283.44
Financing Cash Flow
126.40
+178.80%
45.34
-0.34%
45.49
+3865.91%
1.15
Cash Flow From Continuing Financing Activities
126.40
+178.80%
45.34
-0.34%
45.49
+3865.91%
1.15
Net Issuance Payments Of Debt
—
0.00
+100.00%
-12.50
0.00
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
0.00
+100.00%
-12.50
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
0.00
+100.00%
-12.50
0.00
Net Long Term Debt Issuance
—
0.00
+100.00%
-12.50
0.00
Net Common Stock Issuance
126.02
+185.26%
44.18
-23.26%
57.56
0.00
Common Stock Payments
-0.19
+0.52%
-0.19
-76.36%
-0.11
0.00
Repurchase Of Capital Stock
-0.19
+0.52%
-0.19
-76.36%
-0.11
0.00
Proceeds From Stock Option Exercised
0.11
-86.25%
0.78
+1241.38%
0.06
-92.54%
0.78
Net Other Financing Charges
0.27
-28.27%
0.38
+3.80%
0.37
-0.54%
0.37
Changes In Cash
19.10
+126.87%
-71.09
-173.29%
97.00
+309.19%
-46.37
Beginning Cash Position
58.94
-54.67%
130.03
+293.65%
33.03
-58.40%
79.40
End Cash Position
78.05
+32.41%
58.94
-54.67%
130.03
+293.65%
33.03
Free Cash Flow
-99.30
-51.98%
-65.34
+39.81%
-108.55
+2.59%
-111.44
Interest Paid Supplemental Data
—
0.00
-100.00%
0.99
-39.04%
1.62
Income Tax Paid Supplemental Data
—
0.00
-100.00%
1.00
0.00
Amortization Of Securities
-2.74
+49.18%
-5.40
-42.60%
-3.78
-629.97%
0.71
Common Stock Issuance
126.21
+184.45%
44.37
-23.07%
57.67
0.00
Issuance Of Capital Stock
126.21
+184.45%
44.37
-23.07%
57.67
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category